Company News
Mineralys Shows 9.6 mmHg BP Drop in CKD
Mineralys Therapeutics presented Phase 3 lorundrostat data showing 9.6 mmHg placebo‑adjusted systolic BP reduction in CKD patients at week 12.
Among 192 CKD participants, 71% were on three or more ant
